Understanding Momentum Shifts in (ZVRA)
This article from Stock Traders Daily analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting conflicting sentiment and a mid-channel oscillation pattern. It presents an exceptional risk-reward short setup and outlines three AI-generated trading strategies for different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Did One-Off-Boosted Q1 Profits Just Shift Zevra Therapeutics' (ZVRA) Investment Narrative?
Zevra Therapeutics reported strong Q1 2026 profits of US$37.89 million, a significant turnaround from a net loss, driven partly by unusual items. This profit spike, alongside recent shareholder dilution, raises questions about the quality and repeatability of earnings, especially concerning the funding of its rare disease therapies like MIPLYFFA and OLPRUVA. Investors are urged to scrutinize how Zevra plans to fund future growth without further equity issuance, considering past free cash flow issues.
A Look At Zevra Therapeutics (ZVRA) Valuation After Strong Earnings And SDX Portfolio Sale
Zevra Therapeutics (ZVRA) is currently undervalued, trading at a steep discount to an implied US$23 target price, despite strong first-quarter 2026 earnings and the sale of its SDX portfolio. The company has transitioned to cash-generating commercial sales with the FDA approval of Miplyffa for Niemann-Pick disease type C, fortifying its balance sheet with a $100M Priority Review Voucher sale. The market's current valuation of ZVRA as a speculative biotech may not fully account for its high-margin, recurring revenue potential from its rare disease monopoly.
Zevra Therapeutics (ZVRA) legal chief sells 1,794 shares under 10b5-1 plan
Zevra Therapeutics' Chief Legal & Compliance Officer, Rahsaan Thompson, sold 1,794 shares of common stock at $11.30 per share through an open-market transaction. This sale was pre-scheduled under a Rule 10b5-1(c) trading plan adopted on January 8, 2026. Following the transaction, Thompson directly holds 48,125 shares of ZVRA common stock.
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Zevra Therapeutics announced that its executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at 9:00 a.m. ET in New York. Management will also be available for one-on-one meetings, and a live webcast will be accessible on the company's investor relations website. Zevra Therapeutics is a commercial-stage company focused on providing therapies for rare diseases, with a lead product already marketed in the U.S. for Niemann-Pick disease type C.
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Zevra Therapeutics will be presenting at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026, at 9:00 a.m. ET in New York. Members of Zevra's executive leadership team will represent the company, and management will also be available for one-on-one meetings with registered conference attendees. A webcast of the presentation will be available on the Investor Relations section of Zevra’s website.
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Zevra Therapeutics announced that its executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at 9:00 a.m. ET. Management will also be available for one-on-one meetings, and a live webcast link will be provided on the company's investor relations website. Zevra is a commercial-stage company focused on developing and marketing therapies for rare diseases.
[144] ZEVRA THERAPEUTICS, INC. SEC Filing
This article details ZEVRA THERAPEUTICS, INC.'s SEC Form 144 filing, indicating a proposed sale of securities. The document provides information about the filer, issuer, and the securities to be sold, including details of acquisition and an approximate sale date of May 11, 2026. The filing has a neutral impact and sentiment according to the source.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus "Moderate Buy" rating from brokerages, with an average 1-year price target of $23.33. The company recently exceeded quarterly earnings expectations, reporting an EPS of $0.18 and revenue of $36.22 million. Analyst revisions have been largely positive, leading to an expected full-year EPS of $0.52, and institutional investors hold 35.03% of the stock.
Number of shareholders of Zevra Therapeutics, Inc. – NASDAQ:ZVRA
This article provides financial information for Zevra Therapeutics, Inc. (NASDAQ: ZVRA), including its number of shareholders. It is presented on the TradingView platform, which offers various financial tools and market data services. The content is primarily a listing on a financial data platform rather than a narrative article.
Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed
Zevra Therapeutics reported strong Q1 2026 results with sales of US$36.22 million and a net income of US$37.89 million, driven by the sale of its SDX portfolio and debt retirement. The company has refocused on rare diseases, showing early success with MyPlifer and progress on celiprolol, while holding a significant cash position. This financial turnaround and strategic pivot aim to reshape its investment narrative.
ZVRA Maintained by Guggenheim -- Price Target Raised to $25.00
Guggenheim maintained a "Buy" rating for Zevra Therapeutics (ZVRA) and raised its price target from $23.00 to $25.00, reflecting positive sentiment and growth prospects. GuruFocus indicates ZVRA is undervalued by 47.5% with a current price of $11.55 against a GF Value of $22.02, despite some concerns about profitability and insider selling. Investors are advised to consider both the analyst's positive outlook and the company's financial metrics before making investment decisions.
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Investors Eye 107% Upside Potential
Zevra Therapeutics (ZVRA) presents a compelling investment opportunity in the biotechnology sector, specializing in rare diseases. With a market cap of $650.27 million and a share price of $11, analysts project a 107.07% upside potential, setting an average target price of $22.78 backed by nine buy ratings. The company boasts a promising pipeline of therapies in clinical trials, exceptional revenue growth of 183.40%, and strong technical indicators, despite a negative free cash flow, making it a stock to watch for high-growth potential in healthcare.
Zevra Therapeutics Q1 2026 Earnings: Revenue Surges 78% to $36.2M
Zevra Therapeutics reported a significant revenue increase of 78% to $36.2 million in Q1 2026, ending the quarter with a strong cash position of $236.8 million and no debt. The company also divested non-core assets for $50 million and successfully launched MyPlifer for Niemann-Pick disease type C, receiving 170 prescription enrollment forms. Furthermore, Zevra is advancing its late-stage asset, ciliprole, for vascular Ehlers-Danlos syndrome.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) reported strong Q1 2026 results, beating earnings expectations with an EPS of $0.60 against an expected $0.06. Total net revenue increased by 78% year-over-year to $36.2 million, driven by MyPlifer sales and global Expanded Access Program reimbursements. The company also divested non-core assets for $50 million, paying down debt, and is advancing its late-stage asset, ciliprole, through a Phase III study for vascular Ehlers-Danlos syndrome (VEDS).
Zevra Therapeutics (ZVRA) Q1 earnings and revenues surpass estimates
This article indicates that Zevra Therapeutics (ZVRA) has reported first-quarter earnings and revenues that exceeded analyst estimates. No further details are available in the provided content.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics reported strong first-quarter 2026 financial results, with net revenue increasing 78% to $36.2 million and a net income of $37.9 million. This performance was driven by continued sales of MIPLYFFA and the $50.0 million sale of the SDX portfolio, which also enabled the company to repay its term loan debt. Zevra ended the quarter with a robust cash position of $236.8 million, supporting its strategic priorities and ongoing clinical development, including the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome.
Zevra Therapeutics Q1 Earnings Call Highlights
Zevra Therapeutics reported strong Q1 2026 financials, with net revenue up 78% year-over-year to $36.2 million, largely driven by MIPLYFFA sales and global EAP reimbursements. The company also became debt-free after a one-time gain from the sale of its SDX portfolio and made significant progress with its late-stage celiprolol program and commercial momentum for MIPLYFFA in Niemann-Pick disease type C. Zevra retains a strong balance sheet with $236.8 million in cash and investments, positioning it for continued growth in rare diseases.
Zevra Therapeutics (ZVRA) turns profit, clears $63M debt with SDX sale
Zevra Therapeutics (ZVRA) reported a net profit of $37.9 million for the quarter ended March 31, 2026, a significant improvement from a loss in the prior year. This turnaround was largely driven by higher product sales, particularly MIPLYFFA, and a $43.3 million gain from the sale of its serdexmethylphenidate (SDX) portfolio to Commave Therapeutics. The company utilized proceeds from this sale to fully repay approximately $63.1 million in long-term debt, ending the quarter debt-free with $95.6 million in cash and cash equivalents and $141.2 million in investments.
Earnings call transcript: Zevra Therapeutics Q1 2026 beats expectations with strong revenue growth
Zevra Therapeutics reported exceptional financial results for Q1 2026, significantly exceeding earnings and revenue forecasts, leading to a 6.03% stock increase in aftermarket trading. The company achieved a 78% year-over-year revenue growth and debt-free status, driven by strong sales of MIPLYFFA and its Global Expanded Access Program. Executives highlighted strategic initiatives for continued growth, expanding market access, and advancing late-stage product pipeline, including Celiprolol for vEDS.
Zevra (NASDAQ: ZVRA) swings to Q1 profit and repays term loan
Zevra Therapeutics reported a significant financial turnaround in Q1 2026, swinging to a net profit of $37.9 million, or $0.60 per diluted share, from a net loss in Q1 2025. This was largely driven by a 78% increase in net revenue to $36.2 million and a one-time $43.3 million gain from the sale of its SDX portfolio. The company utilized these proceeds to completely repay its $63.1 million term loan, ending the quarter debt-free with $236.8 million in cash, cash equivalents, and securities.
Zevra Therapeutics: Q1 Earnings Snapshot
Zevra Therapeutics, Inc. reported a Q1 net income of $37.9 million, or 60 cents per share. Adjusted earnings were 18 cents per share, surpassing Wall Street expectations of 6 cents per share. The company's revenue of $36.2 million also exceeded analysts' forecasts.
FMR LLC reports 3.21M-share stake in Zevra Therapeutics (NASDAQ: ZVRA)
FMR LLC has reported a beneficial ownership of 3,211,876.51 shares, representing 5.5% of Zevra Therapeutics (NASDAQ: ZVRA) common stock, as of March 31, 2026. The Schedule 13G filing indicates that FMR LLC holds sole dispositive power over these shares, with implications for dividends or sale proceeds potentially extending to other persons. Abigail P. Johnson is also listed with sole dispositive power for the same amount of shares.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics announced its first-quarter 2026 financial results, reporting a net revenue of $36.2 million, a 78% increase from Q1 2025. The company also highlighted the completion of a $50.0 million sale of its SDX portfolio and the repayment of its term loan debt, leading to a strong cash position of $236.8 million and a debt-free balance sheet. Progress was noted in MIPLYFFA sales and pipeline development, including enrollment in the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome.
Zevra Therapeutics: Q1 Earnings Snapshot
Zevra Therapeutics (ZVRA) reported strong first-quarter results, with net income reaching $37.9 million, or 60 cents per share. Adjusted earnings of 18 cents per share significantly beat analyst expectations of 6 cents per share. The specialty pharmaceutical company also exceeded revenue forecasts, posting $36.2 million against an anticipated $31.4 million.
Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday
Zevra Therapeutics (ZVRA) is scheduled to announce its Q1 2026 earnings after market close on Wednesday, May 6th, with analysts expecting $0.06 EPS and $31.96 million in revenue. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $23.00, though insider selling has been noted recently. Shares are trading around $9.74, with a market capitalization of $575.8 million and a P/E ratio of 7.32.
Discipline and Rules-Based Execution in ZVRA Response
Quantitative Research Desk provides an analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting conflicting sentiment across horizons and an exceptional 58.7:1 risk-reward setup. The analysis includes position, momentum breakout, and risk hedging strategies tailored to different risk profiles. Key findings indicate a mid-channel oscillation pattern and a target of 18.9% gain versus 0.3% risk.
Zevra Therapeutics rises amid takeover speculation
This article reports on Zevra Therapeutics' stock price increase due to speculation about a potential takeover. The brief content available indicates market reaction to unconfirmed acquisition interest.
Zevra Therapeutics (Nasdaq:ZVRA) - Stock Analysis
Zevra Therapeutics (NasdaqGS:ZVRA) is a commercial-stage company focused on rare diseases, currently trading at a significant discount to its fair value. Analysts forecast strong earnings growth and a potential stock price increase, especially following the FDA approval of Miplyffa for Niemann-Pick disease type C. The company's recent strong financial performance and upcoming results demonstrate its growth potential in the rare disease market.
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Zevra Therapeutics (NasdaqGS: ZVRA) will report its Q1 2026 financial and corporate results on Wednesday, May 6, 2026, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results. Details for accessing the webcast and dial-in information for the call have been provided for investors and interested parties.
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Zevra Therapeutics announced it will report its Q1 2026 corporate and financial results on Wednesday, May 6, 2026, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day, with details for accessing both available on its investor relations website. A webcast replay will be available for 90 days.
Zevra Therapeutics schedules first quarter 2026 results release and webcast for May 6
Zevra Therapeutics has announced it will release its first quarter 2026 financial results and provide a corporate update on Wednesday, May 6, 2026, through a live webcast at 4:30 p.m. ET. The event will cover the company's progress and plans within the rare diseases sector. This follows Zevra's earlier participation in AANAM 2026 to engage with the neurology community on Niemann-Pick disease type C.
Zevra to release first-quarter results after market close May 6
Zevra Therapeutics (NasdaqGS: ZVRA) announced it will report its first-quarter 2026 corporate and financial results via a news release after market close on Wednesday, May 6, 2026. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same day. Investors can access the webcast and replay on Zevra's investor relations website, with telephone dial-in details provided for the call.
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) announced it will report its corporate and financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results. Event details, including a link to the webcast and dial-in information, are available on the investor relations section of Zevra’s website.
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Zevra Therapeutics, Inc. announced it will release its first-quarter 2026 corporate and financial results on Wednesday, May 6, 2026, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results. Details for accessing the webcast and telephone dial-in information are provided.
ZVRA Forecast, Price Target & Analyst Ratings | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA)
This article provides an in-depth analysis of ZEVRA THERAPEUTICS INC (NASDAQ: ZVRA), including analyst consensus price targets, earnings forecasts, and historical ratings. Analysts anticipate a significant price increase of 123.64% to an average target of $23.46, with the next earnings report expected on May 11, 2026. The company also shows strong long-term growth forecasts for EPS, revenue, and EBIT.
Zevra Therapeutics (NasdaqGS:ZVRA) Stock Forecast & Analyst Predictions
Zevra Therapeutics is projected to see significant growth, with earnings and revenue expected to increase by 27.9% and 24.9% per annum respectively. Analysts maintain a fair value estimate of $26.00, with some street price targets around $23.00, driven by the launch and market penetration of Miplyffa, potential EU approval, and other pipeline developments. Recent updates show some shifts in EPS estimates but highlight ongoing bullish sentiment regarding the company's rare disease commercial model.
Zevra Therapeutics to Engage Neurology Community at AANAM 2026 Booth in Chicago
Zevra Therapeutics announced its participation in the AANAM 2026 conference in Chicago, scheduled for April 18 to 22. The company will host booth number 4834 to engage with the neurology community and highlight its ongoing research into Niemann-Pick disease type C (NPC). This presence aims to connect with experts and raise awareness for rare neurological conditions.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts
Zevra Therapeutics (NASDAQ:ZVRA) has received a "Moderate Buy" consensus recommendation from analysts, with seven buy ratings and two hold ratings. The average 12-month price target is set at $23.00, significantly higher than its current share price of $10.32. Key points also highlight insider stock sales totaling $1.06 million in the last three months and Zevra's clinical pipeline, including lead candidate KP1077 in Phase 2 for idiopathic hypersomnia.
ZVRA SEC Filings - Zevra Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan offers a comprehensive resource for Zevra Therapeutics (ZVRA) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It provides access to regulatory disclosures, AI-powered summaries of key points, real-time updates from EDGAR, and specialized views for tracking insider transactions. Recent filings discuss insider stock sales, the former CFO's equity awards tied to his departure, the appointment of an interim principal financial officer, and Q3 2025 financial results.
ZVRA SEC Filings - Zevra Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Zevra Therapeutics' (ZVRA) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. It leverages AI-powered summaries to simplify complex documents, offers real-time updates, and details recent insider transactions and financial reports. The platform aims to provide investors with a structured view of Zevra's financial condition and operational updates.
Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA
Stratos Wealth Partners LTD. significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 78.6% in the fourth quarter of the previous year, now owning 409,000 shares valued at approximately $3.67 million. Despite this institutional accumulation, company insiders have been net sellers, divesting over 114,000 shares in the last 90 days. ZVRA currently holds a "Moderate Buy" consensus rating from analysts, with an average target price of $23.00, while trading around $9.74.
Zevra Therapeutics (NASDAQ: ZVRA) posts $106.5M 2025 revenue; proxy items
Zevra Therapeutics announced 2025 net revenue of $106.5 million, with $87.4 million from MIPLYFFA, reporting 161 enrollment forms and 52 new patient enrollments for the therapy. The company also strengthened its financial position by selling a Rare Pediatric Disease Priority Review Voucher for $150 million, leading to the full repayment of its term loan. Zevra is preparing for its 2026 Annual Meeting on June 4, 2026, where shareholders will vote on electing directors, ratifying the auditor, and declassifying the Board.
(ZVRA) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA) using algorithmic entry frameworks. It highlights divergent sentiment readings, a challenging support level, and an exceptional risk-reward setup targeting a 20.1% gain. The piece outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones based on AI-generated signals and multi-timeframe analysis.
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA
JPMorgan Chase & Co. significantly increased its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the third quarter, adding 410,823 shares to hold a total of 438,984 shares valued at approximately $4.18 million. Despite this institutional interest, company insiders have been net sellers, with CEO Neil McFarlane selling 91,000 shares and total insider sales amounting to 114,158 shares worth about $1.06 million in the last 90 days. Analysts maintain a "Moderate Buy" consensus rating for Zevra Therapeutics, with an average target price of $23.00, while the stock currently trades around $9.40.
Zevra Therapeutics Earnings Call Signals Profitable Turn
Zevra Therapeutics reported a significant turnaround to profitability in 2025, driven by strong MIPLYFFA sales, which contributed 82% of its full-year revenue. The company achieved $83.2 million in net income, reversing a $105.5 million loss from the previous year, and ended 2025 with $238.9 million in cash. While facing challenges such as quarterly revenue volatility and slow progress in a Phase III trial for celiprolol, Zevra emphasized its solid financial position, regulatory advancements in Europe, and success in securing U.S. market access for MIPLYFFA.
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA
Hennion & Walsh Asset Management Inc. invested $1.25 million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA), acquiring 139,591 shares in the 4th quarter of 202X. This investment constitutes about 0.25% of Zevra Therapeutics, with institutional investors now holding 35.03% of the company's stock. The article also notes recent insider selling by the CEO and another insider, alongside a "Moderate Buy" analyst consensus with an average price target of $23.00, significantly above the current trading price of around $9.40.
Vanguard realignment: affiliates to report ZVRA holdings separately (ZVRA)
The Vanguard Group has filed an amended Schedule 13G/A for Zevra Therapeutics (ZVRA), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment at Vanguard, where certain subsidiaries will now report their holdings separately, citing SEC Release No. 34-39538. The filing clarifies that this is an administrative reporting change and not a modification to Zevra Therapeutics' outstanding shares or dilution.
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K
John B. Bode, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 78,400 shares valued at $326,928, as reported in a recent SEC filing. The company shows strong revenue growth of 183.36% and favorable profitability metrics like a high gross margin and above-average EPS. While its debt-to-equity ratio is higher than the industry average, its market capitalization and EV/EBITDA ratio suggest potential undervaluation.
How (ZVRA) Movements Inform Risk Allocation Models
This article analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA) using AI models, highlighting conflicting sentiment across different time horizons and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis indicating support and resistance levels. The analysis aims to help traders optimize position sizing and minimize drawdown risk by leveraging institutional-grade AI signals.
